INVO Fertility Incorporates PRP Therapy

Summary

On June 30, 2025, INVO Fertility, Inc. (NASDAQ: IVF), a medical company based in Wisconsin and Florida, announced the inclusion of platelet-rich plasma (PRP) therapy in its fertility services at the Wisconsin Fertility Institute Center. This advanced therapy aims to provide more options for individuals and couples facing fertility issues, showcasing the center’s commitment to pioneering and personalized medical solutions.

Impact Analysis

This event is classified at the company level as it directly pertains to INVO Fertility’s strategic initiative to enhance its fertility services. The introduction of PRP therapy could potentially improve the company’s service offerings, attracting more patients and increasing revenue. This move aligns with the company’s recent focus on its core mission as a fertility company following the sale of its controlling stake in Naya Therapeutics Inc. Reuters+ 2. With the added context of their recent financial performance and strategic realignments, this initiative might help mitigate losses and capitalize on market opportunities presented by current government policies supporting fertility care Benzinga. Investment opportunities could arise in the form of potential stock price appreciation if this development results in increased patient acquisition and revenue growth.